金迪克(688670) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥12,468,040.78, representing a decrease of 58.50% compared to the same period last year[5] - The net profit attributable to shareholders was -¥2,641,751.10, and the net profit after deducting non-recurring gains and losses was -¥6,850,483.65, both classified as not applicable[5] - The net cash flow from operating activities decreased by 83.66%, amounting to ¥6,134,019.46[5] - Total operating revenue for Q1 2022 was CNY 12,468,040.78, a decrease of 58.5% compared to CNY 30,044,808.74 in Q1 2021[20] - Total operating costs for Q1 2022 were CNY 21,145,299.52, down 43.7% from CNY 37,645,517.67 in Q1 2021[20] - Net loss for Q1 2022 was CNY 2,641,751.10, an improvement from a net loss of CNY 5,294,732.69 in Q1 2021[21] - The company reported a gross profit margin of approximately -70.5% in Q1 2022, compared to -20.7% in Q1 2021[20] - The company’s total liabilities as of Q1 2022 were CNY 276,603,531.94, a decrease from CNY 293,119,657.58 in Q1 2021[20] - The total equity attributable to shareholders was CNY 1,458,728,409.59 in Q1 2022, slightly down from CNY 1,461,370,160.69 in Q1 2021[20] - Basic and diluted earnings per share for Q1 2022 were both CNY -0.03, an improvement from CNY -0.09 in Q1 2021[21] Cash Flow and Investments - The net cash flow from investing activities was 63,593,297.03, compared to a negative cash flow of -89,929,121.58 in the previous period[25] - The total cash outflow from investing activities amounted to 71,261,786.05, while the previous period recorded 90,110,091.60[25] - Cash inflow from financing activities was 10,000,000.00, down from 76,760,000.00 in the previous period[25] - The net cash flow from financing activities was 9,844,444.45, significantly lower than 73,465,202.36 in the previous period[25] - The net increase in cash and cash equivalents was 79,571,760.94, compared to 21,073,452.90 in the previous period[25] - The ending balance of cash and cash equivalents reached 116,257,683.14, up from 109,087,225.38 in the previous period[25] - The company paid 155,555.55 in dividends and interest, a decrease from 3,294,797.64 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,735,331,941.53, a decrease of 1.09% from the end of the previous year[6] - The company reported a total current asset of RMB 987,446,356.87, down from RMB 1,069,701,592.05 at the end of 2021[16] - The total non-current assets increased to RMB 747,885,584.66 from RMB 684,788,226.22 year-over-year[17] - Cash and cash equivalents amounted to RMB 116,257,683.14, significantly up from RMB 36,685,922.20[16] - The company’s accounts receivable decreased to RMB 279,300,504.19 from RMB 342,755,037.35[16] - The company’s inventory increased to RMB 54,779,472.06 from RMB 27,977,602.20[16] - Short-term borrowings rose to RMB 20,021,388.88 from RMB 10,010,694.44[17] - The company’s total assets were RMB 1,735,331,941.53, slightly down from RMB 1,754,489,818.27[17] Research and Development - Research and development expenses totaled ¥5,623,502.12, accounting for 45.10% of operating revenue, an increase of 16.37 percentage points year-on-year[6] - The company is actively engaged in research and development, with ongoing projects progressing normally[14] - Research and development expenses for Q1 2022 were CNY 2,949,671.40, down 49.3% from CNY 5,815,948.24 in Q1 2021[20] Market and Sales - The decline in operating revenue was attributed to a decrease in sales volume of the quadrivalent influenza vaccine due to the impact of the COVID-19 pandemic[10] - The company highlighted the seasonal nature of its flu vaccine sales, with peak sales occurring from September to December[14] Financial Management - The company experienced a significant increase in cash and cash equivalents, with a rise of 216.90% due to the maturity and redemption of financial products[9] - The company’s financial expenses decreased by 109.59%, mainly due to a reduction in borrowing and interest expenses[10] - The company did not apply the new accounting standards starting from 2022[25]